DrugPatentWatch Database Preview
Captopril - Generic Drug Details
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What are the generic drug sources for captopril and what is the scope of freedom to operate?
Captopril
is the generic ingredient in seven branded drugs marketed by Par Pharm, Acp Nimble, Apotex, Apothecon, Boscogen, Dava Pharms Inc, Egis Pharms, G And W Labs Inc, Hikma Intl Pharms, Mylan, Oxford Pharms, Prinston Inc, Purepac Pharm, Sandoz, Teva, Watson Labs, Wockhardt Ltd, Yaopharma Co Ltd, Ivax Sub Teva Pharms, and Vintage Pharms Llc, and is included in thirty NDAs. Additional information is available in the individual branded drug profile pages.There are fifteen drug master file entries for captopril. Fifteen suppliers are listed for this compound.
Summary for captopril
| US Patents: | 0 |
| Tradenames: | 7 |
| Applicants: | 20 |
| NDAs: | 30 |
| Drug Master File Entries: | 15 |
| Suppliers / Packagers: | 15 |
| Bulk Api Vendors: | 96 |
| Clinical Trials: | 35 |
| Patent Applications: | 7,483 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price trends for captopril |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for captopril |
| DailyMed Link: | captopril at DailyMed |
Recent Clinical Trials for captopril
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Wuhan University | Phase 2 |
| Centro Neurológico de Pesquisa e Reabiitação, Brazil | Early Phase 1 |
| Tanta University | N/A |
Pharmacology for captopril
| Drug Class | Angiotensin Converting Enzyme Inhibitor |
| Mechanism of Action | Angiotensin-converting Enzyme Inhibitors |
Medical Subject Heading (MeSH) Categories for captopril
Synonyms for captopril
| (-)-Captopril |
| ((S)-3-mercapto-2-methylpropanoyl)-L-proline |
| (2S)-1-((2S)-2-methyl-3-sulfanylpropanoyl)pyrrolidine-2-carboxylic acid |
| (2S)-1-(3-Mercapto-2-methylpropionyl)-L-proline |
| (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid |
| (S)-1-((S)-3-mercapto-2-methylpropanoyl)pyrrolidine-2-carboxylic acid |
| (S)-1-(3-Mercapto-2-methyl-1-oxo-propyl)-L-proline |
| (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline |
| [2S]-1-[3-Mercapto-2-methylpropionyl]-L-proline |
| 1-((2S)-2-Methyl-3-sulfanylpropanoyl)-L-proline # |
| 1-((2S)-3-Mercapto-2-methylpropionyl)-L-proline |
| 1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline |
| 1-(D-3-Mercapto-2-methyl-1-oxopropyl)-L-proline (S,S) |
| 1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline |
| 1-[(2S)-3-Mercapto-2-methyl-1-oxopropyl]-L-proline |
| 1-[(2S)-3-Mercapto-2-methylpropionyl]- L-proline |
| 1-[(2s)-3-mercapto-2-methylpropionyl]-l-proline |
| 1-[(S)-3-mercapto-2-methyl-1-oxopropyl]-L-proline |
| 1-Pyrrolidinecarboxylic acid, 1-(D-3-mercapto-2-methyl-1-propionyl)-, L-(S,S)- |
| 138452-88-7 |
| 1j37 |
| 225661-74-5 |
| 3-Mercapto-2-methylpropionyl-proline |
| 54254-EP2269989A1 |
| 54254-EP2270011A1 |
| 54254-EP2272841A1 |
| 54254-EP2277879A1 |
| 54254-EP2287165A2 |
| 54254-EP2287166A2 |
| 54254-EP2292620A2 |
| 54254-EP2295406A1 |
| 54254-EP2298742A1 |
| 54254-EP2298772A1 |
| 54254-EP2298776A1 |
| 54254-EP2298779A1 |
| 54254-EP2301923A1 |
| 54254-EP2301931A1 |
| 54254-EP2301936A1 |
| 54254-EP2305219A1 |
| 54254-EP2305648A1 |
| 54254-EP2308562A2 |
| 54254-EP2308839A1 |
| 571C862 |
| 62571-86-2 |
| 70903-77-4 |
| 9G64RSX1XD |
| AB00052156_17 |
| AB00052156_18 |
| AB00052156-16 |
| AB0007072 |
| AB04252 |
| AB2000455 |
| AC-12047 |
| AC1L2B4L |
| AC1Q29GZ |
| AC1Q5R48 |
| Acediur |
| Aceplus |
| Acepress |
| Acepril |
| AKOS005622581 |
| Alopresin |
| Apopril |
| Apopril (TN) |
| Asisten |
| BBL033600 |
| BC203925 |
| BCP9000485 |
| BDBM21642 |
| BIM-0050290.0001 |
| BPBio1_000063 |
| BRD-K54529596-001-04-0 |
| BRD-K54529596-001-15-6 |
| BSPBio_000057 |
| BSPBio_002976 |
| C 4042 |
| C06867 |
| C9H15NO3S |
| Capoten |
| Capoten (TN) |
| Capozide (Salt/Mix) |
| Captolane |
| Captopril (Capoten) |
| Captopril (JP17/USP/INN) |
| Captopril [USAN:INN:BAN:JAN] |
| Captopril [USAN:USP:INN:BAN:JAN] |
| Captopril for system suitability, European Pharmacopoeia (EP) Reference Standard |
| Captopril, >=98% (HPLC), powder |
| Captopril, 98% |
| Captopril, British Pharmacopoeia (BP) Reference Standard |
| Captopril, European Pharmacopoeia (EP) Reference Standard |
| Captopril, meets USP testing specifications |
| Captopril, Pharmaceutical Secondary Standard; Certified Reference Material |
| Captopril, United States Pharmacopeia (USP) Reference Standard |
| Captopril,(S) |
| Captoprilum |
| Captoprilum [INN-Latin] |
| Captopryl |
| Captoril |
| Captril |
| CCG-39104 |
| Cesplon |
| CHEBI:3380 |
| CHEMBL1560 |
| component of Acezide (Salt/Mix) |
| component of Captea (Salt/Mix) |
| component of Ecazide (Salt/Mix) |
| CPD000059061 |
| CS-2425 |
| D-2-Methyl-3-mercaptopropanoyl-L-proline |
| D-3-Mercapto-2-methylpropanoyl-L-proline |
| D-3-Mercapto-2-methylpropionylproline |
| D00251 |
| DB01197 |
| Dilabar |
| DivK1c_000208 |
| DSSTox_CID_17197 |
| DSSTox_GSID_37197 |
| DSSTox_RID_79306 |
| DTXSID1037197 |
| EI-213 |
| EINECS 263-607-1 |
| Epitope ID:114065 |
| EU-0100302 |
| FAKRSMQSSFJEIM-RQJHMYQMSA-N |
| Farcopril |
| FT-0082749 |
| Garranil |
| Garranil (discontinued) |
| GTPL5158 |
| Hipertil |
| HMS1921C12 |
| HMS2089P19 |
| HMS2092I12 |
| HMS2095C19 |
| HMS2233I04 |
| HMS3259G10 |
| HMS3260N06 |
| HMS3712C19 |
| HMS500K10 |
| HSDB 6527 |
| HY-B0368 |
| Hypertil |
| Hypopress |
| IDI1_000208 |
| Isopresol |
| J10167 |
| KBio1_000208 |
| KBio2_001168 |
| KBio2_003736 |
| KBio2_006304 |
| KBio3_002196 |
| KBioGR_001321 |
| KBioSS_001168 |
| KM0635 |
| KS-00000XHT |
| KS-5025 |
| L-?Proline, 1-?[(2S)?-?3-?mercapto-?2-?methyl-?1-?oxopropyl]?- |
| L-Captopril |
| L-Proline, 1-((2S)-3-mercapto-2-methyl-1-oxopropyl)- |
| L-Proline, 1-(3-mercapto-2-methyl-1-oxopropyl)-, (S)- |
| L-Proline, 1-[(2S)-3-mercapto-2-methyl-1-oxopropyl]- |
| Lopac-C-4042 |
| Lopac0_000302 |
| Lopirin |
| Lopirin [Switzerland] |
| Lopril |
| LP00302 |
| LS-137465 |
| MCULE-1716939647 |
| MFCD00168073 |
| MLS000069484 |
| MLS001076488 |
| MolPort-001-794-639 |
| N-[(S)-3-Mercapto-2-methylpropionyl]-L-proline |
| NC00554 |
| NCGC00015235-01 |
| NCGC00015235-02 |
| NCGC00023654-03 |
| NCGC00023654-04 |
| NCGC00023654-05 |
| NCGC00023654-06 |
| NCGC00023654-07 |
| NCGC00023654-08 |
| NCGC00023654-09 |
| NCGC00023654-10 |
| NCGC00023654-11 |
| NCGC00023654-13 |
| NCGC00260987-01 |
| NINDS_000208 |
| Novocaptopril |
| NSC-757419 |
| NSC757419 |
| Opera_ID_1041 |
| Pharmakon1600-01500682 |
| Prestwick_103 |
| Prestwick3_000019 |
| s2051 |
| SA 333 |
| SAM002564201 |
| SBB017523 |
| SBI-0050290.P004 |
| SCHEMBL4 |
| SMP1_000056 |
| SMR000059061 |
| SPBio_001022 |
| Spectrum_000688 |
| SPECTRUM1500682 |
| Spectrum2_001211 |
| Spectrum3_001388 |
| Spectrum4_000811 |
| Spectrum5_001587 |
| SQ 14,225 |
| SQ 14225 |
| SQ-14,225 |
| SQ-14,534 |
| SQ-14225 |
| SQ-14534 |
| SQ14534 |
| SR-01000000039 |
| SR-01000000039-2 |
| SR-01000075603 |
| SR-01000075603-1 |
| SR-01000075603-3 |
| ST079562 |
| STK802012 |
| Tenosbon |
| Tensiomin |
| Tensobon |
| Tensoprel |
| Tox21_110890 |
| Tox21_110890_1 |
| Tox21_500302 |
| UNII-9G64RSX1XD |
| UPCMLD-DP003 |
| UPCMLD-DP003:001 |
| X8Z |
| Z2786051697 |
| Zapto |
| ZINC57001 |
US Patents and Regulatory Information for captopril
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acp Nimble | CAPTOPRIL | captopril | TABLET;ORAL | 074462-002 | Feb 13, 1996 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Watson Labs | CAPTOPRIL | captopril | TABLET;ORAL | 074451-004 | Feb 13, 1996 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Watson Labs | CAPTOPRIL | captopril | TABLET;ORAL | 074576-004 | Apr 23, 1996 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Purepac Pharm | CAPTOPRIL | captopril | TABLET;ORAL | 074640-004 | Mar 31, 1997 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Acp Nimble | CAPTOPRIL | captopril | TABLET;ORAL | 074433-004 | Feb 13, 1996 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for captopril
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Par Pharm | CAPOTEN | captopril | TABLET;ORAL | 018343-004 | Jun 13, 1995 | Start Trial | Start Trial |
| Par Pharm | CAPOTEN | captopril | TABLET;ORAL | 018343-001 | Approved Prior to Jan 1, 1982 | Start Trial | Start Trial |
| Par Pharm | CAPOTEN | captopril | TABLET;ORAL | 018343-004 | Jun 13, 1995 | Start Trial | Start Trial |
| Par Pharm | CAPOTEN | captopril | TABLET;ORAL | 018343-003 | Approved Prior to Jan 1, 1982 | Start Trial | Start Trial |
| Par Pharm | CAPOTEN | captopril | TABLET;ORAL | 018343-005 | Jan 17, 1985 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2019 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.